Form 4 Filing for Acumen Pharmaceuticals, Inc.

Nathan B. Fountain, a director at Acumen Pharmaceuticals, Inc. (ABOS), reported a transaction on June 3, 2026. He acquired 35,500 shares of Common Stock under transaction code "A", resulting in a post-transaction holding of 54,550 shares. Additionally, he was granted stock options (right to buy) for 53,250 shares of Common Stock, with an exercise price of $2.29 per share. These options are set to vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, contingent upon continuous service. The reported transactions are marked as direct ownership.